TLE1 function and therapeutic potential in cancer

Da Yuan; Xue Yang; Zhenpeng Yuan; Yanqing Zhao; Junchao Guo

doi:10.18632/oncotarget.13278

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

TLE1 function and therapeutic potential in cancer

Da Yuan, Xue Yang, Zhenpeng Yuan, Yanqing Zhao and Junchao Guo _

PDF | HTML | How to cite

Oncotarget. 2017; 8:15971-15976. https://doi.org/10.18632/oncotarget.13278

Metrics: PDF 1853 views | HTML 2737 views | ?

Abstract

Da Yuan1,*, Xue Yang2,*, Zhenpeng Yuan3, Yanqing Zhao4 and Junchao Guo1

1 Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

2 Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China

3 Department of Pediatric Cardiac Surgery, Cardiovascular Institute and Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

4 Institute of Medical Information, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China

* These authors have contributed equally to this work

Correspondence to:

Junchao Guo, email:

Keywords: transducin-like enhancer of split 1; tumor; pancreatic cancer

Received: June 13, 2016 Accepted: November 01, 2016 Published: November 10, 2016

Abstract

Groucho (Gro)/Transducin-like enhancer of split (TLE) family proteins act as co-repressors of many transcription factors, and are involved in key signaling pathways. TLE1 negatively regulates inflammation and has potential roles in various diseases, including cancer. Previous studies suggest TLE1 could be used as a diagnostic marker and is a possible therapeutic target in various malignancies. It is therefore important to elucidate the mechanisms underlying TLE1 function during cancer initiation and metastasis. In this review, we highlight the functions of TLE1 in cancer and explore targeted approaches for cancer diagnosis and treatment. In particular, we discuss the TLE1 function in pancreatic cancer.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 13278

Publication Alerts

Reviews:

TLE1 function and therapeutic potential in cancer

Abstract